with methylphenidate (MPH). The control group consisted of 21 healthy subjects. The PERGs were recorded in a steady state mode in response to checkerboard stimuli of 12 reversals/s. Data collection with people with schizophrenia is ongoing, and results will be reported at SIRS. Results: Before treatment, the patients with ADHD presented with elevated background noise (higher by 127%) in comparison to the control group. After treatment, noise level did not differ from what was observed in the control group. Retinal background noise was found to be highly correlated with the severity of the ADHD symptoms. The results will be discussed in relationship to our findings in patients with schizophrenia. Discussion: These data provide further evidence for the hypothesis that elevated background noise is linked to ADHD and cognitive deficits. The findings are of special relevance because ADHD is a disorder with a dedicated treatment option for cognitive symptoms. Interestingly, a similar pathophysiological mechanism for cognitive dysfunction has been proposed for both schizophrenia and ADHD. However, because ADHD medications, such as MPH, typically elevate dopamine levels, potentially leading to exacerbation of psychotic symptoms, different approaches for treating cognitive symptoms in schizophrenia need to be explored. On this basis, current approaches used to target neuronal noise and cognitive symptoms in patients with schizophrenia will be discussed and their relevance for future research will be addressed. (Meier et al., AJP, 2013), and test for overlap in the genetic variants associated with schizophrenia and retinal microvascular abnormality. Methods: To test whether individuals diagnosed with schizophrenia showed microvascular abnormality, we used data from the Dunedin Study, a representative cohort of 1,000 New Zealanders followed from birth to age 38. The cohort underwent retinal imaging at age 38, and retinal venular (small veins) and arteriolar (small arteries) diameters were obtained. Analyses compared individuals with schizophrenia (n=27), healthy individuals (n=412), and individuals with medical or psychiatric conditions (ns ranged from 110-210) on retinal vessel diameter. To test for overlap in the genetic variants associated with schizophrenia and retinal vessel diameter, we used linkage disequilibrium-score regression (LD regression) to obtain the genetic correlation between schizophrenia and retinal vessel diameter. This method requires only GWAS (genome wide associate studies) summary statistics rather than actual genotypes. Summary statistics for schizophrenia and retinal vessel diameter came from published meta-analyses. Results: Adults diagnosed with schizophrenia had wider retinal venules (standardized mean=0.59) compared with same-age healthy adults (standardized mean=-0.20) and compared with individuals diagnosed with hypertension, diabetes, and tobacco dependence. Findings could not be explained by antipsychotic medication, as venular diameter was similar in the subset of individuals diagnosed with schizophrenia who had not taken antipsychotic medication in the year prior to retinal imaging (n=22; standardized mean=0.69). There were no differences in arteriolar diameter between individuals diagnosed with schizophrenia and all other groups. Results from LD regression showed a small genetic correlation between schizophrenia and
PHENOTYPIC AND GENETIC ASSOCIATIONS
Background: Individuals with schizophrenia are at increased risk for cardiovascular diseases, and this risk cannot be fully explained by antipsychotic medications or lifestyle factors. Retinal imaging offers a non-invasive means of visualizing the microvasculature in living individuals with schizophrenia. Here we test whether individuals with schizophrenia exhibit retinal microvascular abnormality (Meier et al., AJP, 2013) , and test for overlap in the genetic variants associated with schizophrenia and retinal microvascular abnormality. Methods: To test whether individuals diagnosed with schizophrenia showed microvascular abnormality, we used data from the Dunedin Study, a representative cohort of 1,000 New Zealanders followed from birth to age 38. The cohort underwent retinal imaging at age 38, and retinal venular (small veins) and arteriolar (small arteries) diameters were obtained. Analyses compared individuals with schizophrenia (n=27), healthy individuals (n=412), and individuals with medical or psychiatric conditions (ns ranged from 110-210) on retinal vessel diameter. To test for overlap in the genetic variants associated with schizophrenia and retinal vessel diameter, we used linkage disequilibrium-score regression (LD regression) to obtain the genetic correlation between schizophrenia and retinal vessel diameter. This method requires only GWAS (genome wide associate studies) summary statistics rather than actual genotypes. Summary statistics for schizophrenia and retinal vessel diameter came from published meta-analyses. Results: Adults diagnosed with schizophrenia had wider retinal venules (standardized mean=0.59) compared with same-age healthy adults (standardized mean=-0.20) and compared with individuals diagnosed with hypertension, diabetes, and tobacco dependence. Findings could not be explained by antipsychotic medication, as venular diameter was similar in the subset of individuals diagnosed with schizophrenia who had not taken antipsychotic medication in the year prior to retinal imaging (n=22; standardized mean=0.69). There were no differences in arteriolar diameter between individuals diagnosed with schizophrenia and all other groups. Results from LD regression showed a small genetic correlation between schizophrenia and venular diameter (r=0.05, p=.31) and a slightly larger genetic correlation between schizophrenia and arteriolar diameter (r=0.17, p=.02). Discussion: Wider venular diameter is a distinguishing feature of schizophrenia, but genetic variants associated with schizophrenia overlap more strongly with variants associated with arteriolar diameter. It is possible that environmental influences associated with schizophrenia tend to narrow arterioles, obscuring a phenotypic link between schizophrenia and wider arterioles. Pathophysiological mechanisms underlying vessel diameter, including inflammation and endothelial dysfunction, might be related to the development of schizophrenia, and particular genes might contribute to both schizophrenia and arteriolar diameter. Findings will be discussed in relation to links between retinal vessel diameter and IQ (Shalev, Meier et al., Psychol Sci, 2013) and depression (Meier et al., Psychosom Med, 2014) .
Plenary

DECREASING CARDIOVASCULAR RISK IN PERSONS WITH SCHIZOPHRENIA: INTERVENTIONS AND FUTURE DIRECTIONS Gail Daumit Johns Hopkins Medical Institutions
Overall Abstract: Persons with schizophrenia experience two to three times higher mortality than the overall population. This premature death is due in large part to cardiovascular disease and is potentially preventable. All cardiovascular risk factors are elevated in persons with schizophrenia. This presentation will describe the evidence for interventions to reduce cardiovascular risk factors in this vulnerable population, including obesity and tobacco smoking, and will describe models of integrated physical and mental health care. Ongoing research on interventions to decrease cardiovascular risk in schizophrenia will be presented, and future research needs will be discussed including implementation strategies to scale-up interventions to reduce cardiovascular disease risk in community settings.
Concurrent Symposia
DOES BIOLOGY READ THE DSM? TRANSDIAGNOSTIC FINDINGS IN PSYCHOSIS AND IMPLICATIONS FOR TREATMENT Michael Owen Cardiff University
Overall Abstract: A major emerging issue in schizophrenia research is the degree to which the mechanisms underlying the disorder are specific to schizophrenia or are common to a number of disorders, potentially indicating common and distinct pathways to illness. Understanding this is important for diagnosis, biomarkers and the development of new treatments. This symposium will bring together new data to consider the latest findings from different genetic, imaging and clinical approaches. Dr. Owen, Wales, will present the latest genetic data from the largest genome-wide genetic analyses to date in psychotic disorders (schizophrenia and bipolar disorder) and neurodevelopmental disorders (autism, intellectual disability and ADHD), comprising samples from over 100,000 patients and controls. These data identify novel shared pathways involving neurodevelopmental genes, synaptic function and histone modification that are common across these disorders, but also identify differences in the degree of involvement of particular pathways. Dr. Howes, England, will present new data from neurochemical and structural imaging studies comparing patients across psychotic and neurodevelopmental disorders (including schizophrenia, bipolar disorder people
